> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tarrex Biopharma IND for Colorectal Cancer Therapy
- URL: https://www.fdaweb.com/tarrex-biopharma-ind-for-colorectal-cancer-therapy/
- Published: 2017-03-21T12:00:00.000Z
- Updated: 2026-09-14T22:12:43.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138260

Tarrex Biopharma has submitted an IND for TX803, a novel treatment for colorectal cancer. TX803 is a first-in-class small molecule therapeutic that “inhibits the PI3K/AKT pathway through a novel mechanism – by targeting, not the kinase itself, but a PI3K activating onco-protein, the truncated retinoid X receptor alfa (tRXRa),” the company says. “Moreover, tRXRa is found in high levels in tumor tissues obtained from a significant portion of colorectal, gastric and breast cancer patients.”

  
The company says its preclinical studies have demonstrated that TX803 is orally bioavailable, well tolerated, and efficacious in several animal tumor models, including KRAS mutated colorectal cancer. Tarrex has licensed the therapy’s worldwide rights from the Sanford Burnham Prebys Medical Discovery Institute in San Diego, CA.